Duke Resident Physician-Scientist Program- NIAID

医生-科学家队伍一直是许多重大发现的重要驱动力 传染病、免疫性和过敏性疾病在过去二十年里。然而，临床医生-科学家的管道 由于临床培训的复杂性和要求，见习生一直在减少，在此之后，债务不断增加 医学院，NIH支付线的下降，以及重要的是，在临床期间缺乏研究指导 训练。在接受了四年或更长时间的住院医生培训后，几乎没有时间或支持研究工作，在那里 对于以研究为导向的受训者来说，启动或重新启动研究存在许多障碍。这是一个很大的差距 在内科科学家的发展过程中，他们准备在他们的 事业。多学科杜克大学科学家-临床医生-研究人员的主要目标是促进 驻院期间研究(Duke SCI-STARR)计划是培训内科科学家在所有方面的 生物医学研究，以培养将领导开发、实施和 诊断、治疗和预防传染病、免疫学和变态反应的新临床模式的评价 儿童和成人的疾病。杜克SCI-STAR将对三个部门的住院医生进行培训：儿科， 整个生物医学研究连续体(基础/翻译，早期)领域的医学和外科 阶段临床试验和药代动力学，以及后期临床试验和结果)，主题为 在整个生命过程中改善健康。该计划将包括四个培训目标：1)综合性 涵盖基础、翻译、临床研究和专业发展的教学；2)发展 完成研究项目和个性化的职业发展计划；3)建立 学术活动的记录；以及4)有资格获得董事会认证并继续攻读专科 训练。DUKE SCI-STAR将由MPIs执行委员会(EC)领导，Sallie Permar，医学博士 (儿科)，Scott Palmer，MD，MHS(内科)，David HarpolJr，MD(外科)，以及SCI-Starr 每个部门的副项目主任，以及扩展的派驻项目执行委员会 主任和计划协调员，并将利用一支由22个多部门、多学科、 资金雄厚，经验丰富的教员。此应用程序请求支持三个常驻- 研究人员每年为每个受训人员提供18-24个月的研究支持。在完成 计划，这些人将能够成功地过渡到研究密集型奖学金培训 竞争外部资金以支持独立之路，并成为下一代 医生指导和指导学员进行以临床为导向的过敏、免疫学和感染学研究 影响儿童和成人的疾病。该方案目标的实现将满足紧急的医疗需求 支持：1)全国各地医学院的学术内科科学家和导师；2)创新 和临床翻译的新战略，以改善个人在整个生命过程中的健康。

The physician-scientist workforce has been an important driver for many of the substantial discoveries in infectious, immunologic, and allergic diseases over the last two decades. Yet, the pipeline of clinician-scientist trainees has been in decline, fueled by complexity and requirements of clinical training, mounting debt after medical school, declining NIH paylines, and importantly, lack of access to research mentorship during clinical training. After four or more years of residency training with little time or support for research endeavors, there are many hurdles for research-oriented trainees to initiate or re-initiate research. This represents a major gap in the development of physician-scientists prepared to translate research into the clinical arena during their careers. The primary goal of the multidisciplinary Duke Scientist-Clinician-Investigator Stimulating access to Research during Residency (Duke SCI-StARR) program is to train physician-scientists in all aspects of biomedical research in order to cultivate investigators who will lead the development, implementation, and evaluation of new clinical modalities to diagnose, treat and prevent infectious, immunologic and allergic diseases in children and adults. Duke SCI-StARR will train residents across 3 departments: Pediatrics, Medicine, and Surgery in areas along the full biomedical research continuum (basic/translational, early phase clinical trials and pharmacokinetics, and late phase clinical trials and outcomes) with a theme of improving health over the life course. The program will consist of four training aims: 1) comprehensive didactics covering basic, translational, and clinical research and professional development; 2) development and completion of a research project and an individualized career development plan; 3) establishment of a track record of scholarly activity; and 4) eligibility for board certification and continuation to subspecialty training. Duke SCI-StARR will be led by an Executive Committee (EC) of MPIs Sallie Permar, MD, PhD (Pediatrics), Scott Palmer, MD, MHS (Medicine), and David Harpole, Jr, MD (Surgery), and a SCI-StARR Associate Program Director from each department, along with an Expanded EC of Residency Program Directors and Program Coordinators, and will capitalize on a team of 22 multi-departmental, multi-disciplinary, well-funded, and experienced faculty preceptors. This application requests support for three Resident- Investigators each year with each trainee to be supported for 18-24 months of reseach. Upon completion of the program, these individuals will be capable of transitioning to research-intense fellowship training, successfully competing for extramural funding to support a path to independence, and becoming the next generation of physicians leading and mentoring trainees in clinically-oriented research of allergy, immunology, and infectious diseases affecting children and adults. Acheivement of the program's objectives will fulfill urgent medical needs for: 1) academic physician-scientists and mentors in medical schools throughout the country and 2) innovations and clinical translation of novel strategies to improve the health of individuals across the life course.